Oncogenesis

Scope & Guideline

Fostering global collaboration in cancer discovery.

Introduction

Explore the comprehensive scope of Oncogenesis through our detailed guidelines, including its aims and scope. Stay updated with trending and emerging topics, and delve into declining areas to understand shifts in academic interest. Our guidelines also showcase highly cited topics, featuring influential research making a significant impact. Additionally, discover the latest published papers and those with high citation counts, offering a snapshot of current scholarly conversations. Use these guidelines to explore Oncogenesis in depth and align your research initiatives with current academic trends.
LanguageEnglish
ISSN2157-9024
PublisherSPRINGERNATURE
Support Open AccessYes
CountryUnited States
TypeJournal
Convergefrom 2012 to 2024
AbbreviationONCOGENESIS / Oncogenesis
Frequency1 issue/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressCAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND

Aims and Scopes

The journal Oncogenesis focuses on the molecular mechanisms underlying cancer development and progression, with an emphasis on innovative therapeutic strategies and the exploration of cancer biology through advanced methodologies.
  1. Molecular Mechanisms of Cancer:
    Research articles delve into the intricate molecular pathways that contribute to cancer initiation, progression, and metastasis, including studies on signaling pathways, genetic mutations, and epigenetic modifications.
  2. Cancer Therapeutics and Resistance:
    The journal publishes findings related to the development of novel therapeutic approaches, including targeted therapies and immunotherapies, as well as mechanisms of drug resistance that hinder treatment efficacy.
  3. Cancer Stem Cells and Tumor Microenvironment:
    A significant focus is placed on cancer stem cells, their role in tumor heterogeneity, and the influence of the tumor microenvironment on cancer progression and treatment response.
  4. Advancements in Diagnostic and Prognostic Techniques:
    The journal highlights innovative diagnostic tools and prognostic markers that facilitate early detection and personalized treatment strategies for various cancer types.
  5. Translational Research and Clinical Applications:
    Oncogenesis emphasizes studies that bridge laboratory findings with clinical applications, aiming to translate basic research into effective cancer treatments.
Recent publications in Oncogenesis reflect the emergence of new themes and trends that are shaping the future of cancer research, indicating areas of increasing interest and innovation.
  1. Targeting the Tumor Microenvironment:
    Research is increasingly focusing on the tumor microenvironment and its role in cancer progression, therapy resistance, and immune evasion, highlighting the importance of understanding the interactions between tumor cells and their surrounding stromal cells.
  2. Cancer Metabolism and Bioenergetics:
    There is a growing trend towards investigating the metabolic reprogramming of cancer cells, with studies exploring how alterations in metabolism contribute to tumor growth and therapeutic resistance.
  3. Immunotherapy and Immune Checkpoint Inhibition:
    The exploration of immunotherapeutic strategies, particularly immune checkpoint inhibitors, is rapidly expanding, with research dedicated to understanding mechanisms of action, resistance, and combination therapies.
  4. Precision Medicine and Personalized Therapy:
    The journal is witnessing an increase in studies aimed at developing personalized treatment strategies based on genetic and molecular profiling of tumors, paving the way for more effective and tailored therapies.
  5. Role of Non-Coding RNAs in Cancer:
    Emerging research on the functional roles of non-coding RNAs (such as microRNAs and long non-coding RNAs) in cancer biology is gaining traction, providing insights into their potential as therapeutic targets and biomarkers.

Declining or Waning

While Oncogenesis continues to thrive in many areas, some themes have shown a decline in frequency, reflecting shifts in research focus and advancements in the field.
  1. Traditional Chemotherapy Studies:
    Research focused solely on traditional chemotherapy regimens is becoming less prevalent, as newer targeted therapies and immunotherapies gain prominence in cancer treatment, leading to a reduced emphasis on conventional approaches.
  2. Single Agent Studies:
    There is a noticeable decrease in publications centered around the efficacy of single-agent treatments, as the field increasingly prioritizes combination therapies that enhance treatment outcomes and reduce resistance.
  3. Basic Histopathological Studies:
    Basic histopathological studies that do not integrate molecular or genetic insights are being overshadowed by more comprehensive approaches that utilize multi-omics and systems biology to understand cancer biology.
  4. Epidemiological Studies without Molecular Insights:
    Epidemiological studies that lack a molecular component are becoming less frequent, as the emphasis shifts toward understanding the biological mechanisms driving cancer disparities and outcomes.

Similar Journals

MOLECULAR CANCER THERAPEUTICS

Advancing cancer therapy through molecular insights.
Publisher: AMER ASSOC CANCER RESEARCHISSN: 1535-7163Frequency: 12 issues/year

MOLECULAR CANCER THERAPEUTICS, published by the American Association for Cancer Research, is a premier journal dedicated to advancing the field of cancer research and therapy since 2001. With a notable impact factor reflecting its high-quality content, this journal stands out in the Q1 category for both Cancer Research and Oncology as of 2023. Researchers, clinicians, and students interested in innovative treatment strategies and molecular mechanisms can find valuable insights within its pages, bolstered by a rigorous peer-review process and a global perspective on cancer therapeutic developments. Although the journal operates under a subscription model, it provides comprehensive access to cutting-edge studies and reviews that drive forward the understanding of cancer biology and treatment modalities. The journal's impressive Scopus rankings further validate its influence within both oncology and the broader cancer research community, making it an indispensable resource for anyone committed to combating cancer through science.

CANCER RESEARCH

Pioneering insights into cancer biology and treatment.
Publisher: AMER ASSOC CANCER RESEARCHISSN: 0008-5472Frequency: 24 issues/year

Cancer Research, published by the American Association for Cancer Research, is a premier journal in the field of oncology, renowned for its commitment to advancing cancer research since its inception in 1941. With an impressive impact factor reflecting its vital role in the field, this journal consistently ranks in the Q1 quartile for both Cancer Research and Oncology, positioning it among the top 7.5% of journals in these categories. The journal serves as a crucial platform for researchers, professionals, and students to disseminate and gain insights into groundbreaking studies that shape our understanding of cancer biology, prevention, diagnosis, and treatment. While it is not an open-access publication, its rigorous peer-review process ensures that only high-quality research is published, thus maintaining a standard of excellence in the scientific community. With a strong legacy and an ever-expanding influence, Cancer Research continues to be essential for anyone dedicated to the fight against cancer, showcasing cutting-edge research that drives scientific discovery and innovation.

ONCOGENE

Exploring the Frontiers of Cancer Genetics and Therapy
Publisher: SPRINGERNATUREISSN: 0950-9232Frequency: 50 issues/year

ONCOGENE is a premier peer-reviewed journal published by SpringerNature, serving as a crucial platform for innovative research within the fields of Cancer Research, Genetics, and Molecular Biology. With an impressive Impact Factor and a distinguished Q1 ranking across major categories, ONCOGENE publishes cutting-edge studies aimed at unraveling the complexities of cancer biology and genetic mechanisms. The journal has been a vital resource for the academic community since its inception in 1987, and it continues to foster rigorous scientific discussions and collaborations. Researchers, professionals, and students can access a wealth of critical insights and advances in cancer genomics and therapeutic approaches, cementing ONCOGENE’s role as a leading voice in the landscape of biomedical research. For comprehensive academic research, ONCOGENE remains an indispensable source of knowledge with contributions that significantly impact the evolution of cancer research and treatment strategies.

ANTICANCER RESEARCH

Illuminating Paths in Cancer Treatment and Prevention
Publisher: INT INST ANTICANCER RESEARCHISSN: 0250-7005Frequency: 12 issues/year

ANTICANCER RESEARCH, published by the International Institute of Anticancer Research, stands at the forefront of cancer-related scholarly communication. With ISSN 0250-7005 and E-ISSN 1791-7530, this esteemed journal has been serving the global research community since 1981, showcasing innovative research aimed at combating cancer through various therapeutic approaches and scientific inquiry. Based in Greece, the journal aims to disseminate vital findings in the fields of Cancer Research, Medicine, and Oncology, reflecting its notable categorization in the Q3 and Q2 quartiles as of 2023. Despite its rigorous peer-review process and the absence of open access, ANTICANCER RESEARCH remains a vital publication for researchers, clinicians, and students eager to stay updated on the evolving landscape of anticancer strategies. As it converges to its milestone year of 2024, the journal continues to enrich the discourse around cancer treatment and prevention, affirming its position as an essential resource for those dedicated to advancing knowledge in anticancer therapies.

GENES CHROMOSOMES & CANCER

Exploring the Genetic Foundations of Cancer Progression.
Publisher: WILEYISSN: 1045-2257Frequency: 12 issues/year

GENES CHROMOSOMES & CANCER, published by Wiley, is a premier journal in the intertwined fields of cancer research and genetics. With an ISSN of 1045-2257 and an e-ISSN of 1098-2264, this journal has been a significant outlet for innovative research since its inception in 1989, continuing through to 2024. Positioned in the Q2 quartile of both Cancer Research and Genetics categories in 2023, it reflects a strong impact in the scientific community, as evidenced by its Scopus rankings—99th in Genetics and 83rd in Cancer Research. Though it does not provide open access options, GENES CHROMOSOMES & CANCER offers valuable insights that foster collaboration and discovery among researchers, professionals, and students dedicated to understanding the genetic underpinnings of cancer. With its reputable standing, this journal is a vital resource for those aspiring to contribute meaningful advancements in cancer genetics and therapeutic interventions.

Molecular Cancer

Pioneering open access to vital cancer insights.
Publisher: BMCISSN: Frequency: 1 issue/year

Molecular Cancer, published by BMC, stands as a premier open access journal dedicated to advancing our understanding of cancer biology, treatment, and prevention since its inception in 2002. With an impressive Q1 ranking in the domains of Cancer Research, Molecular Medicine, and Oncology, this journal occupies a significant position in the academic landscape, emphasizing high-quality research that influences clinical practices and future studies. The journal is indexed in leading databases with exceptional Scopus ranks, reflecting its rigorous peer-review process and impactful contributions to the field, where it ranks in the top 2-3 positions across various relevant categories. Based in the United Kingdom, Molecular Cancer offers researchers worldwide a valuable platform for disseminating innovative findings that drive the biomedical community forward. The journal's open access model ensures that groundbreaking research is freely accessible, fostering collaboration and knowledge sharing among professionals, students, and academics alike. Explore cutting-edge developments in cancer research through Molecular Cancer and join a community committed to improving patient outcomes and advancing scientific discovery.

CANCER GENE THERAPY

Shaping the Future of Cancer Research and Therapy
Publisher: SPRINGERNATUREISSN: 0929-1903Frequency: 12 issues/year

Cancer Gene Therapy, published by SpringerNature, stands at the forefront of research in the fields of cancer research, molecular biology, and molecular medicine. With a robust impact factor reflecting its significant influence—ranking in the Q2 category for cancer research and Q1 for both molecular biology and molecular medicine—it serves as an essential resource for scholars and practitioners alike. Since its inception in 1994, the journal has dedicated itself to advancing the understanding and therapeutic application of genetic innovations in oncology. Notably, it holds distinguished Scopus ranks, placing it among the top tier journals in its categories, underscoring its importance to the scientific community. While open access options are not available, the compelling research published here offers invaluable insights into the latest advancements and strategies in cancer therapy. Engaging with *Cancer Gene Therapy* not only keeps professionals informed but also inspires future innovations in the quest for effective cancer treatments.

Cancer Research Communications

Empowering global collaboration in cancer research.
Publisher: AMER ASSOC CANCER RESEARCHISSN: Frequency: 1 issue/year

Cancer Research Communications is an esteemed journal published by the American Association for Cancer Research, a leading organization in the field of oncology. This journal aims to advance knowledge in cancer research through the dissemination of high-quality, peer-reviewed articles that cover a wide range of topics related to cancer biology, treatment modalities, and prevention strategies. As an open-access journal, Cancer Research Communications ensures that vital research findings are accessible to a global audience, promoting collaboration and innovation within the scientific community. The journal serves as a crucial platform for researchers, professionals, and students to share their insights and foster the exchange of effective cancer therapies and methodologies. With a commitment to excellence, it plays a significant role in shaping the future of cancer research and therapeutic development.

Advances in Cancer Biology-Metastasis

Innovating Insights into Cancer Metastasis.
Publisher: ELSEVIERISSN: Frequency: 4 issues/year

Advances in Cancer Biology-Metastasis is an emerging journal published by Elsevier, aimed at advancing our understanding of the complexities of cancer biology, with a specific focus on the mechanisms and pathways related to metastasis. With an E-ISSN of 2667-3940, this journal offers a platform for researchers, professionals, and students in the fields of Cancer Research and Cell Biology to disseminate innovative findings and discuss novel therapeutic approaches. Though currently classified in the Q4 quartile across both Cancer Research and Cell Biology categories, the journal aspires to enhance its impact through rigorous peer review and high-quality publication. Positioned to cover the years from 2021 to 2024, it seeks to bridge gaps in foundational knowledge and promote collaborative research efforts that could pivot the current understanding of cancer metastasis. Researchers are encouraged to take advantage of this platform to advocate for advancements in cancer biology, making significant contributions that can influence both academic and clinical practices.

CELLULAR & MOLECULAR BIOLOGY LETTERS

Illuminating Cellular Processes Through Open Access Research
Publisher: BMCISSN: 1425-8153Frequency: 1 issue/year

CELLULAR & MOLECULAR BIOLOGY LETTERS, published by BMC, is a premier open-access journal dedicated to disseminating high-quality research in the fields of Biochemistry, Cell Biology, and Molecular Biology. Established in 1996, the journal has emerged as a leader in its domain, boasting an impressive Q1 ranking across three critical categories as of 2023, reflecting its significant impact within the scientific community. With an ISSN of 1425-8153 and an E-ISSN of 1689-1392, it offers accessible research findings to a global audience, having been open access since 2013. Situated in the United Kingdom, at CAMPUS, 4 CRINAN ST, LONDON N1 9XW, the journal continues to serve as a vital resource for researchers, professionals, and students, contributing to advancements in the understanding of cellular and molecular processes. By providing a platform for original research, reviews, and short communications, CELLULAR & MOLECULAR BIOLOGY LETTERS plays a crucial role in fostering dialogue and collaboration within the scientific community.